China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted agents are approved to treat this indication: Roche’s Herceptin and Jiangsu Hengrui Medicine’s AiTan. Herceptin is the first-line standard of care for HER2-positive patients and AiTan is approved for third-line patients, irrespective of HER2 status. Several novel targeted therapies—including angiogenesis inhibitors (Eli Lilly’s Cyramza and Chi-Med’s Elunate); a claudin inhibitor (Ganymed’s zolbetuximab), and combination regimens of PD-1/PD-L1 inhibitors (Bristol-Myers Squibb’s Opdivo, Merck & Co.’s Keytruda, Innovent Biologics’ Tyvyt, and Suzhou Jiangsu Hengrui Medicine’s camrelizumab);—and biosimilars of Herceptin are in late-stage development. The launch and uptake of these novel therapies will lead to significant growth of the gastric cancer therapy market over the 2018-2028 forecast period. However, the need for additional, effective targeted therapies will remain high, representing a lucrative commercial opportunity for drug developers.
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.
Qualitative and quantitative insights from five thought-leading medical oncologists in China, supported by survey data collected for this and other DRG research.
Diagnosed prevalence of gastric cancer by HER2 biomarker status and by disease stage. Clinically and market-relevant drug-treatable populations.
Ten-year, annualized, drug-level sales and patient shares of key gastric cancer therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 10 drugs; Phase II: >10 drugs; coverage of select early-phase products.